Evaluation of potential instruments for quantifying necrobiosis lipoidica severity via physician evaluation and patient-reported outcomes

J Am Acad Dermatol. 2023 Dec;89(6):1305-1306. doi: 10.1016/j.jaad.2023.08.048. Epub 2023 Aug 25.

Authors

David A Hashemi¹, Caroline A Nelson², Mary Nyberg³, Maya Das³, Misha Rosenbach⁴

Affiliations

¹ Harvard Combined Dermatology Residency Training Program, Harvard Medical School, Boston, Massachusetts.
² Department of Dermatology, Yale School of Medicine, New Haven, Connecticut.
³ Processa Pharmaceuticals, Hanover, Maryland.
⁴ Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania. Electronic address: Misha.Rosenbach@pennmedicine.upenn.edu.

PMID: 37633461
DOI: 10.1016/j.jaad.2023.08.048

No abstract available

Keywords: color; diabetes; granulomatous disease; inflammation/inflammatory; medical dermatology; necrobiosis lipoidica; quality of life; ulcers.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Humans
Necrobiosis Lipoidica* / diagnosis
Patient Reported Outcome Measures